Workflow
Compass Therapeutics(CMPX)
icon
Search documents
Compass Therapeutics Completes Patient Enrollment in COMPANION-002, a Randomized Study of CTX-009 in Combination with Paclitaxel, and Provides an Update on the Development Plan in Biliary Tract Cancer
Newsfilter· 2024-08-06 12:00
Core Insights - Compass Therapeutics has completed enrollment of 150 patients in the COMPANION-002 trial, a Phase 2/3 study evaluating CTX-009 in patients with unresectable advanced metastatic or recurrent biliary tract cancers [1][4] - The company has received approval for an Investigator Sponsored Trial (IST) to study CTX-009 in the first-line setting for biliary tract cancer, which will be conducted at The University of Texas MD Anderson Cancer Center [3] Group 1: COMPANION-002 Trial - The COMPANION-002 study is a multi-center, open-label, randomized trial comparing CTX-009 plus paclitaxel to paclitaxel alone in patients who have received one prior systemic chemotherapy regimen [4] - The primary endpoint of the trial is the overall response rate (ORR), with secondary endpoints including progression-free survival (PFS), overall survival (OS), clinical benefit rate (CBR), and duration of response (DOR) [4] - The trial is being conducted at 33 clinical sites across the United States [4] Group 2: CTX-009 Overview - CTX-009 is a bispecific antibody that blocks Delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A) signaling pathways, which are essential for angiogenesis and tumor vascularization [5] - Preclinical and early clinical data suggest that CTX-009 provides robust anti-tumor activity across various solid tumors, including colorectal, gastric, cholangiocarcinoma, pancreatic, and non-small cell lung cancer [5] - Partial responses to CTX-009 as a monotherapy have been observed in heavily pre-treated cancer patients resistant to approved anti-VEGF therapies [5] Group 3: Company Background - Compass Therapeutics is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for multiple diseases, particularly in oncology [6] - The company's scientific focus includes the relationship between angiogenesis, the immune system, and tumor growth, with a pipeline targeting critical biological pathways for effective anti-tumor responses [6] - Founded in 2014 and headquartered in Boston, Massachusetts, Compass aims to advance its product candidates through clinical development as standalone therapies and in combination with other proprietary antibodies [6]
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: Here's Why
ZACKS· 2024-07-10 17:00
Compass Therapeutics, Inc. (CMPX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. Individual investors often find it hard to make decisions based on rating upgrades by Wall Street analysts, since these are mostly driven by subjective factors that are hard to see and measure in real time. In these situations, the Zacks rating system come ...
Compass Therapeutics: Pointing Right At Some Tough Cancers
Seeking Alpha· 2024-06-20 07:14
alengo/E+ via Getty Images Topline Summary Compass Therapeutics (NASDAQ:CMPX) is an oncology-focused developmental biotech working on novel immunotherapies to treat different forms of solid tumor, with the most notable shots on goal being in the gastrointestinal cancers space. They have experienced significant declines in valuation through 2023 and 2024, despite being deep in late-stage clinical study. So today I want to take a look at their projects, what they've shared to date, and the outlook for potenti ...
Compass Therapeutics Announces CEO Transition
Newsfilter· 2024-05-28 20:10
Investor Contact ir@compasstherapeutics.com Media Contact "Vered has been a valued member of our executive team," added Carl L. Gordon, Chairman of the Board. "We thank Vered for her significant contributions to Compass and wish her the very best in her future endeavors." About Compass Therapeutics Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass's scientific focus is on the ...
Compass Therapeutics(CMPX) - 2024 Q1 - Quarterly Report
2024-05-13 12:01
_____________________________ For the transition period from _________________ to _________________ Registrant's telephone number, including area code: (617) 500-8099 _____________________________ Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ ...
Compass Therapeutics(CMPX) - 2024 Q1 - Quarterly Results
2024-05-13 12:00
Compass Therapeutics Reports 2024 First Quarter Financial Results and Provides Corporate Update Enrollment is progressing well in COMPANION-002, a Phase 2/3 randomized study of CTX-009 (DLL4 x VEGF-A bispecific antibody) in patients with advanced biliary tract cancer (BTC). Enrollment is expected to be completed by mid-year 2024 with top-line data expected in the first quarter of 2025. Advanced CTX-8371 (PD-1 x PD-L1 bispecific antibody) into a first-in-human clinical study and dosed the first patient in Ap ...
Compass Therapeutics Receives FDA Fast Track Designation for the Investigation of CTX-009 in Combination with Paclitaxel for the Treatment of Patients with Metastatic or Locally Advanced Biliary Tract Tumors That Have Been Previously Treated
Newsfilter· 2024-04-25 12:00
CTX-009, the Company's bispecific DLL4/VEGF-A antibody, in combination with paclitaxel, has shown promising clinical responses in patients with advanced biliary tract cancer (BTC) in its Phase 2 study Top-line data readout for COMPANION-002, the Company's randomized Phase 2/3 BTC U.S. study, is expected by the end of 2024 BOSTON, April 25, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based ther ...
Compass Therapeutics Announces Poster Presentations at the Cholangiocarcinoma Foundation 2024 Annual Conference
Newsfilter· 2024-04-12 12:00
BOSTON, April 12, 2024 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (NASDAQ:CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced poster presentations on CTX-009, the Company's bispecific DLL4/VEGF-A antibody, at the Cholangiocarcinoma Foundation (CCF) 2024 Annual Conference to be held at the Salt Palace Convention Center in Salt Lake City, Utah from April 17–19, 2024. Presentation Details: P ...
Compass Therapeutics Presents Data Demonstrating Elimination of MHC Class I Negative Tumors in In Vivo Models at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Newsfilter· 2024-04-09 16:00
Major Histocompatibility Complex Class I (MHC-I) negative tumors are refractory to immune-oncology therapies, including resistance to checkpoint blockers, due to the loss of the fundamental recognition of the tumor by CD8+ T-Cells, which drive the adaptive immune attack on the tumor. Immune responses were generated toward the MHC-I negative tumors by combining CTX-009 with CTX-471. This combination was surprisingly synergistic. The proposed mechanism for this effect suggests the involvement of NK-cells, whi ...
3 Penny Stocks With the Power to 10X Your $1K Investment
InvestorPlace· 2024-03-24 20:00
Today we will be looking at three penny stocks with the power to 10x your $1K investment. The three firms discussed below have outsized potential to turn a small capital allocation into a much larger return.Two of the three firms discussed below have very strong catalysts on their side. The other operates in the biotech sector which is notoriously volatile. Regardless, all three have a lot of untapped potential. Penny stocks are no different than any others from the perspective that good businesses create g ...